Bayer in Gene Therapy Collaboration With Mammoth Biosciences

By Reuters
Reuters
Reuters
January 10, 2022 Updated: January 10, 2022

FRANKFURT—Bayer on Monday struck a partnership deal with Mammoth Biosciences to develop therapeutic tools based on CRISPR/CAS9 gene editing as the German drug maker seeks to widen its cell and gene therapy development efforts.

Unlisted U.S. biotech firm Mammoth will initially receive $40 million from Bayer plus potential milestone payments of more than $1 billion contingent on scientific and commercial achievements.

The initial focus of the collaboration will be liver-based diseases, the companies said in a joint statement on Monday.

Mammoth, headquartered in the San Francisco Bay area, was co-founded by Nobel laureate Jennifer Doudna. She shared the 2020 Nobel Prize in Chemistry with Emmanuelle Charpentier for developing the CRISPR/CAS9 gene editing tool.

Among previous steps to build a cell and gene therapy business, Bayer acquired BlueRock Therapeutics and Asklepios Biopharmaceutical in 2019 and 2020, respectively.

In late 2020, it agreed on an alliance on anti-tumour immune cell therapies with Atara Biotherapeutics.

By Ludwig Burger and Patricia Weiss